Initial results of RETINA IMPLANT Alpha AMS trial published
Posted by Andreas Winkler on September 21st, 2017
(Reutlingen) - The scientific journal Frontiers in Neuroscience has published a report on the functionality of Retina Implant AG?s (https://www.retina-implant.de/en/)RETINA IMPLANT Alpha AMS subretinal implant. The joint article by a group of experts headed by Eberhart Zrenner, Senior Professor of Ophthalmology at the Werner Reichardt Centre for Integrative Neuroscience, which forms part of the Institute for Ophthalmic Research at the Eberhard Karls University of T?bingen, relates to clinical experience with a group of patients who had the latest version of the chip implanted at various hospitals in Europe.
In the article, entitled "Interim Results of a Multicenter Trial with the New Electronic Subretinal Implant Alpha AMS in 15 Patients Blind from Inherited Retinal Degenerations", lead author Dr.Katharina Stingl from the T?bingen Institute for Ophthalmic Research and other doctors and scientists involved in the trial describe how the chip performed.
Study:
Stingl K., Schippert R., Bartz-Schmidt K. U., Besch D., Cottriall C. L., Edwards T. L., Gekeler F., Greppmaier U., Kiel K., Koitschev A., K?hlewein L., MacLaren R. E., Ramsden J. D., Roider J., Rothermel A., Sachs H., Schr?der G. S., Tode J., Troelenberg N. and Zrenner E. (2017): Interim Results of a Multicenter Trial with the New Electronic Subretinal Implant Alpha AMS in 15 Patients Blind from Inherited Retinal Degenerations. Frontiers in Neuroscience. 11:445. doi: 10.3389/ fnins.2017.00445.
http://journal.frontiersin.org/article/10.3389/fnins.2017.00445/full
About Retina Implant AG
Retina Implant AG researches and develops innovative treatments and high-tech products for people suffering from retinitis pigmentosa (RP). The subretinal RETINA IMPLANT Alpha AMS can help blind patients regain a certain degree of useful sight. The CE-approved microchip is implanted beneath the retina (subretinally) at specialist RI implantation centres.
Transcorneal electrical stimulation (TES treatment) with the RI OkuStim? system offers RP patients with sufficient residual vision the opportunity to slow down the progression of the dis-ease.
The company, based in Reutlingen, employs around 45 people and is managed by Reinhard Rubow (CEO and speaker of the Management Board), J?rgen Klein (Member ot the Board, Sales & Marketing) and Dr. Alfred Stett (CTO, Member of the Board).
Company-Contact
Retina Implant AG
Ines W?lker
Gerhard-Kindler-Str. 13
72770 Reutlingen
Phone: + 49 71 21 3 64 03 - 289
E-Mail: ines.wuelker@retina-implant.de
Url: implant.de
Press
Zeeb Kommunikation GmbH
Anja P?tzold
Hohenheimer Stra?e 58a
70184 Stuttgart
Phone: 0711-60 70 719
E-Mail: info@zeeb.info
Url: http://www.zeeb-kommunikation.de
